Bejjani Ghassan K, Zabramski Joseph
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
J Neurosurg. 2007 Jun;106(6):1028-33. doi: 10.3171/jns.2007.106.6.1028.
Dural substitutes are often needed after neurosurgical procedures to expand or replace dura mater resected during surgery. A new dural repair material derived from porcine small intestinal submucosa (SIS) was evaluated in a prospective multicenter clinical study.
Between 2000 and 2003, 59 patients at five different institutions underwent dural reconstruction with the SIS dural substitute, with a minimum follow up of 6 months. The primary goals of the study were to assess the efficacy and safety of the SIS dural substitute according to the rate of cerebrospinal fluid (CSF) leakage, infection, and meningitis. Chiari malformation Type I decompression (32 patients) and tumor resection (18 patients) were the most common procedures performed, with 81% of SIS grafts implanted in the posterior fossa or spine. There was one case of a CSF leak (1.7%), two cases of wound infection (3.4%), and no cases of bacterial meningitis (0%) in the 58 patients available for follow up. In both cases of wound infection, the SIS graft acted as a barrier to infection and was not removed. Intraoperatively, a watertight seal was achieved in all 59 cases. On follow-up imaging available in 27 patients there was no evidence of any adverse reaction to the graft or of cerebral inflammation.
The SIS dural substitute demonstrated substantial efficacy in these patients after a mean follow up of 7.3 +/- 2.2 months. Rates of infection, CSF leakage, and meningitis were comparable to those reported for other dural substitute materials. A lack of adverse reactions to the graft, favorable safety profile, and clinical efficacy all point to the utility of this material as an alternative for dural repair.
神经外科手术后常需要使用硬脑膜替代物来扩大或替代手术中切除的硬脑膜。在一项前瞻性多中心临床研究中对一种源自猪小肠黏膜下层(SIS)的新型硬脑膜修复材料进行了评估。
在2000年至2003年期间,五个不同机构的59例患者接受了使用SIS硬脑膜替代物的硬脑膜重建术,最短随访时间为6个月。该研究的主要目标是根据脑脊液(CSF)漏、感染和脑膜炎的发生率评估SIS硬脑膜替代物的有效性和安全性。I型Chiari畸形减压术(32例患者)和肿瘤切除术(18例患者)是最常见的手术,81%的SIS移植物植入后颅窝或脊柱。在可进行随访的58例患者中,有1例发生脑脊液漏(1.7%),2例发生伤口感染(3.4%),无细菌性脑膜炎病例(0%)。在两例伤口感染中,SIS移植物起到了感染屏障的作用,未被移除。术中,所有59例均实现了水密密封。在27例患者的随访影像学检查中,没有证据表明移植物有任何不良反应或脑部炎症。
在平均随访7.3±2.2个月后,SIS硬脑膜替代物在这些患者中显示出显著疗效。感染、脑脊液漏和脑膜炎的发生率与其他硬脑膜替代材料报道的发生率相当。对移植物无不良反应、良好的安全性和临床疗效均表明该材料可作为硬脑膜修复的替代物。